Does Slower Organic Growth Undermine the Automation and M&A Story at Applied Industrial Technologies (AIT)?

• In recent commentary, Applied Industrial Technologies has been flagged for underperformance in its core business, with organic revenue and earnings growth over the past two years trailing industry peers and highlighting a heavier dependence on acquisitions to sustain expansion.
• This weaker internal growth profile, combined with only modestly projected sales improvement, raises questions about how effectively Applied can balance acquisition-driven growth with the health of its underlying operations.
• We’ll now examine how concerns around Applied’s softer organic growth profile may influence the existing investment narrative built on automation and M&A.

Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Applied Industrial Technologies Investment Narrative Recap

To own Applied Industrial Technologies, you need to believe its automation and solutions focus, combined with disciplined capital allocation, can offset softer organic growth and a reliance on acquisitions. The recent news of underwhelming organic revenue and EPS growth versus peers directly reinforces the biggest near term risk: that acquisition led expansion could outpace the strength of the core business. For now, this underperformance does not appear to materially alter the main short term catalyst, which remains execution against current growth and margin targets.

The latest Q3 2026 earnings release is particularly relevant here, with modest year on year sales and EPS gains alongside raised full year guidance for total sales growth and earnings. That combination highlights the tension between headline growth targets and the weaker organic trends flagged in recent commentary, and it puts more weight on how effectively Applied can convert incremental revenue into sustainable, high quality earnings. It also frames upcoming results as an important check on whether automation and M&A are really compensating for...

Read the full narrative on Applied Industrial Technologies (it's free!)

Applied Industrial Technologies' narrative projects $5.6 billion revenue and $492.8 million earnings by 2029.

Uncover how Applied Industrial Technologies' forecasts yield a $330.00 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span roughly US$214 to US$330 per share, showing how far apart individual views can be. You should weigh that spread against the risk that ongoing muted demand in key legacy end markets could limit Applied Industrial Technologies’ ability to grow organically and support its current performance profile, and consider how different assumptions about those markets lead to very different conclusions.

Explore 4 other fair value estimates on Applied Industrial Technologies - why the stock might be worth as much as 7% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Applied Industrial Technologies research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Applied Industrial Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Applied Industrial Technologies' overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com